|
Early Infant Feeding and Epigenetic Modification in Tumor Suppressor Genes
|
1R03CA139406-01A1
|
$83,648
|
$33,459
|
Merewood, Anne
|
BOSTON MEDICAL CENTER
|
|
Oncogenic NOTCH Signaling
|
5P01CA119070-04
|
$1,012,243
|
$415,020
|
ASTER, JON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Targeting MLL As Anticancer Therapy for Infant Acute Lymphoblastic Leukemia
|
1R43CA141903-01
|
$130,694
|
$130,694
|
Burkhart, Catherine
|
BUFFALO BIOLABS, LLC
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-05
|
$318,664
|
$79,666
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL BOSTON
|
|
Promoting Treatment Adherence in Adolescent Leukemia
|
5R01CA119162-03
|
$90,274
|
$90,274
|
Drotar, Dennis
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
Empirical Likelihood Bayes Analysis of Quantile Regression Model
|
1R03CA133944-01A2
|
$83,120
|
$41,560
|
Kim, Mi-Ok
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
GENETIC PREDICTORS OF LEUKEMIA THERAPY RESPONSE
|
5R01CA108862-05
|
$256,197
|
$256,197
|
Aplenc, Richard
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
|
5R01CA102646-05
|
$320,964
|
$109,128
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Determinants of Relapse Risk After BMT for ALL
|
5R01CA116660-03
|
$297,760
|
$297,760
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Cancer Center Support Grant
|
3P30CA033572-26S1
|
$94,753
|
$3,790
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S2
|
$107,415
|
$4,297
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S3
|
$100,000
|
$4,000
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-26
|
$2,342,475
|
$93,699
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Minority Predoctoral Fellowship Program
|
5F31CA117055-05
|
$26,091
|
$13,046
|
ORTIZ, SERINA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Roles and Regulation of p53
|
5P01CA087497-09
|
$1,639,011
|
$81,951
|
Prives, Carol
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Cancer Center Clinical Trials Reporting Program (CTRP) Early Adopters
|
3P30CA013696-36S1
|
$99,928
|
$1,999
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-36
|
$3,999,822
|
$79,996
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Mechanisms of T-Cell Leukemogenesis Induced by Notch1
|
5R01CA120196-03
|
$305,900
|
$152,950
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of AKT signaling in NOTCH1 induced leukemias
|
5R01CA129382-02
|
$341,043
|
$170,522
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S2
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S5
|
$143,383
|
$1,434
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-45
|
$11,688,901
|
$116,889
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer and Leukemia Group B
|
2U10CA032291-28
|
$413,820
|
$24,829
|
Burstein, Harold
|
DANA-FARBER CANCER INSTITUTE
|
|
Development of Novel Therapeutic Strategies in Human Leukemias
|
5P01CA066996-12
|
$2,367,210
|
$1,183,605
|
GRIFFIN, JAMES
|
DANA-FARBER CANCER INSTITUTE
|
|
Zebrafish Chemical and Classical Genetics Approach to the Pathogenesis of T-ALL
|
5K08CA133103-02
|
$140,940
|
$140,940
|
Gutierrez, Alejandro
|
DANA-FARBER CANCER INSTITUTE
|
|
Validating Syk as a Target for AML Therapy
|
1R01CA140292-01
|
$357,937
|
$357,937
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer and Leukemia Group B
|
2U10CA047577-22
|
$157,170
|
$9,430
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
Cancer and Leukemia Group B Statistical Center
|
2U10CA033601-30
|
$4,929,147
|
$295,749
|
GEORGE, STEPHEN
|
DUKE UNIVERSITY
|
|
Mechanisms of Leukemogenic Transformation by MLL-CALM
|
5R01CA109281-06
|
$262,921
|
$262,921
|
WECHSLER, DANIEL
|
DUKE UNIVERSITY
|
|
Functions of E2A in B Lymphocyte Development
|
5R01CA072433-12
|
$310,291
|
$155,146
|
Zhuang, Yuan
|
DUKE UNIVERSITY
|
|
MDM2 regulates XIAP gene expression in cancer treatment
|
5R01CA123490-02
|
$257,300
|
$64,325
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
EORTC DATA CENTER
|
5U10CA011488-39
|
$809,323
|
$105,212
|
Sylvester, Richard
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Metabolic Syndrome Following Transplant for Leukemia
|
7R01CA112530-04
|
$501,100
|
$250,550
|
BAKER, KEVIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Pediaric Oncology Research Training Program
|
5T32CA009351-31
|
$223,195
|
$33,479
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
2P30CA015704-35
|
$10,977,925
|
$109,779
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S3
|
$249,999
|
$2,500
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S4
|
$85,601
|
$856
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S5
|
$100,000
|
$1,000
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Biology and Prognostic implications of Flt3 mutations in AML
|
5R01CA114563-05
|
$435,609
|
$217,805
|
MESHINCHI, SOHEIL
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
1R01CA136551-01A1
|
$551,563
|
$275,782
|
Riddell, Stanley
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer and Leukemia Group B
|
2U10CA077597-12
|
$65,608
|
$3,936
|
LIU, MINETTA
|
GEORGETOWN UNIVERSITY
|
|
Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
|
5R01CA086011-09
|
$561,044
|
$561,044
|
BOROWITZ, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
|
Developing FLT3-Targeted Therapy for Pediatric Leukemia
|
5K23CA111728-04
|
$140,130
|
$70,065
|
BROWN, PATRICK
|
JOHNS HOPKINS UNIVERSITY
|
|
Investigating the role of retrotransposons in hematopoietic neoplasias.
|
5K08CA134746-02
|
$139,725
|
$34,931
|
BURNS, KATHLEEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Bone Marrow Transplantation in Human Disease
|
5P01CA015396-34
|
$3,012,562
|
$903,769
|
JONES, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
Hematopoietic Stem Cells for Transplantation
|
5P01CA070970-11
|
$2,096,756
|
$104,838
|
SHARKIS, SAUL
|
JOHNS HOPKINS UNIVERSITY
|
|
FLT3 Tyrosine Kinase Inhibitors as Therapy for Leukemia
|
5R01CA090668-07
|
$293,612
|
$146,806
|
SMALL, DONALD
|
JOHNS HOPKINS UNIVERSITY
|
|
Glucocorticoid Receptor Regulation in Leukemia
|
5R01CA116042-03
|
$242,820
|
$242,820
|
VEDECKIS, WAYNE
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
Molecular genetics of MLL-associated leukemia
|
5P01CA105049-05
|
$1,210,621
|
$605,311
|
DIAZ, MANUEL
|
LOYOLA UNIVERSITY CHICAGO
|
Total relevant funding to Childhood Leukemia for this search: $47,255,992
|